Results 41 to 50 of about 109,598 (309)

TRPM4 contributes to cell death in prostate cancer tumor spheroids, and to extravasation and metastasis in a zebrafish xenograft model system

open access: yesMolecular Oncology, EarlyView.
Transient receptor potential melastatin‐4 (TRPM4) is overexpressed in prostate cancer (PCa). Knockout of TRPM4 resulted in reduced PCa tumor spheroid size and decreased PCa tumor spheroid outgrowth. In addition, lack of TRPM4 increased cell death in PCa tumor spheroids.
Florian Bochen   +6 more
wiley   +1 more source

Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management

open access: yesCancer Communications, Volume 42, Issue 12, Page 1257-1287, December 2022., 2022
Abstract Clustered regularly interspaced short palindromic repeats‐associated protein (CRISPR/Cas9), an adaptive microbial immune system, has been exploited as a robust, accurate, efficient and programmable method for genome targeting and editing. This innovative and revolutionary technique can play a significant role in animal modeling, in vivo genome
Khaled S. Allemailem   +6 more
wiley   +1 more source

Inhibition of Apoptosis in Prostate Cancer Cells by Androgens Is Mediated through Downregulation of c-Jun N-terminal Kinase Activation

open access: yesNeoplasia: An International Journal for Oncology Research, 2008
Androgen deprivation induces the regression of prostate tumors mainly due to an increase in the apoptosis rate; however, the molecular mechanisms underlying the antiapoptotic actions of androgens are not completely understood.
Petra Isabel Lorenzo, Fahri Saatcioglu
doaj   +1 more source

COVID‐19, androgens, and androgenic alopecia [PDF]

open access: yesDermatological Reviews, 2020
AbstractThe severity of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in males may be due to the higher androgen expression. It is also known that androgen sensitivity is correlated with androgenic alopecia. The “Gabrin sign” identifies those with severe androgen alopecia (Hamilton Norwood scale = 3–7) who are at a higher risk for ...
Wambier, Carlos Gustavo   +3 more
openaire   +2 more sources

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

open access: yesMolecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia   +17 more
wiley   +1 more source

Circulating adrenal and gonadal steroid hormones heterogeneity in active young males and the contribution of 11-oxy androgens

open access: yesScientific Reports
The classical androgens, testosterone and dihydrotestosterone, together with dehydroepiandrosterone, the precusrsor to all androgens, are generally included in diagnostic steroid evaluations of androgen excess and deficiency disorders and monitored in ...
Amanda C. Swart   +7 more
doaj   +1 more source

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

open access: yesMolecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source

Molecular and cellular paradigms of multidrug resistance in cancer

open access: yesCancer Reports, Volume 5, Issue 12, December 2022., 2022
Abstract Background The acquisition of resistance to chemotherapy is a major hurdle in the successful application of cancer therapy. Several anticancer approaches, including chemotherapies, radiotherapy, surgery and targeted therapies are being employed for the treatment of cancer.
Foram U. Vaidya   +6 more
wiley   +1 more source

Androgens and prostate disease

open access: yesAsian Journal of Andrology, 2014
A growing body of literature has established the anabolic benefi ts of testosterone (T) therapy in hypogonadal men. However, there remains a paucity of data regarding the risks of exogenous androgen use in older men and the potential for adverse effects ...
Lori A Cooper, Stephanie T Page
doaj   +1 more source

Clinical significance of stratifying prostate cancer patients through specific circulating genes

open access: yesMolecular Oncology, EarlyView.
We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy